MIRA INFORM REPORT

 

 

Report Date :

25.06.2011

 

IDENTIFICATION DETAILS

 

Name :

CIREX PHARMACEUTICALS LIMITED

 

 

Registered Office :

7-2-A2, Hetero Corporate, Industrial Estate, Sanathnagar, Hyderabad 500018, Andhra Pradesh, India

 

 

Country :

India

 

 

Financials (as on) :

31.03.2010

 

 

Date of Incorporation :

21.12.1990

 

 

Com. Reg. No.:

012119

 

 

Capital Investment / Paid-up Capital :

Rs. 7.113 millions

 

 

CIN No.:

[Company Identification No.]

U24239AP1990PLC012119

 

 

Legal Form :

A Closely Held Public Limited Liability Company 

 

 

Line of Business :

Manufacturer of Bulk Drugs and Drug Intermediates

 

 

No. of Employees :

150  Approximately

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba (50)

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

USD 1117812

 

 

Status :

Good

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

 

Comments :

Subject is an established company having satisfactory track. General financial position of the company is good. Trade relations are reported as fair. Business is active. Payments are reported to be regular and as per commitments.

 

The company can be considered good for normal business dealings at usual trade terms and conditions.

 

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – April 1, 2010

 

Country Name

Previous Rating

(31.12.2009)

Current Rating

(01.04.2010)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

LOCATIONS

 

Registered Office :

7-2-A2, Hetero Corporate, Industrial Estate, Sanathnagar, Hyderabad 500018, Andhra Pradesh, India

Tel. No.:

91-40-23704923

E-Mail :

contact_@heterodrugs.com

vasucs@heterodrugs.com

ramu@heterodrugs.com

Website :

http://www.heterodrugs.com

 

 

Factory  :

Gundla Manchnoor Village, Hatnoor Mandal, Medak, Andhra Pradesh, India

 

 

DIRECTORS

 

AS ON 26.08.2010

 

Name :

Dr. B. Partha Saradhi Reddy

Designation :

Director

Address :

Plot No.389, Road No.22/B, Jubilee Hills Check Post, Hyderabad - 500 033, Andhra Pradesh, India

Date of Birth/Age :

06.03.1954

Date of Appointment :

01.04.2000

 

 

Name :

Mr. P. Viswanadha Raju

Designation :

Director Works

Address :

House No. 5601, Srila Builders, Hydernagar, Kukatpally, Hyderabad – 500 072, Andhra Pradesh, India

Date of Birth/Age :

24.07.1955

Date of Appointment :

05.02.1999

 

 

Name :

Mr. K. Ratnakara Reddy

Designation :

Director

Address :

Plot No.102, Sai Spurthi Apartments, Motinagar, Borabanda, Hyderabad - 500 018, Andhra Pradesh, India

Date of Birth/Age :

03.08.1966

Date of Appointment :

01.11.2001

 

 

Name :

Mr. Vamsi Krishna Bandi

Designation :

Director

Address :

Plot No.389, Road, No.22 / B, Jubilee Hills Check Post, Hyderabad – 500 033, Andhra Pradesh, India

Date of Birth/Age :

31.07.1983

Date of Appointment :

11.09.2008

 

 

Name :

Mr. Male Srinivas Reddy

Designation :

Director

Date of Birth/Age :

02.02.1973

Date of Appointment :

26.08.2010

 

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

AS ON 26.08.2010

 

Names of Shareholders

No. of Shares

B. Vamshi Krishna

41470

M. Pera Reddy

4250

P. Viswanadha Raju

2050

M. Madhavi

500

M Karthikeya Reddy

6700

K. Ratnakara Reddy

1050

M. Krishna Sindhuri

14000

Total

70020

 

AS ON 26.08.2010

 

Equity Share Breakup

 

Percentage of Holding

Category

 

 

Directors or relatives of directors

 

100.00

 

Total

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer of Bulk Drugs and Drug Intermediates

 

 

Products :

 

Product Description

ITC Code

Bulk Drugs and Drug Intermediates

294110

 

 

Terms :

 

Selling :

Cash, Credit

 

 

Purchasing :

Cash, Credit

 

PRODUCTION STATUS

 

Particulars

Unit

Installed Capacity

Actual Production

 

Bulk Drugs and Intermediates

Qty (Kgs)

125000

76109

 

Note:

Installed capacity are calculated based on product mix and are as certified by the management an not verified by the auditors, being technical matter.

 

 

 

GENERAL INFORMATION

 

No. of Employees :

150 Approximately

 

 

Bankers :

·         State Bank of Hyderabad

Industrial Estate, Sanathnagar Branch, Sanathnagr, Hyderabad – 500 018, Andhra Pradesh, India

 

 

Facilities :

Rs. In Millions

 

SECURED LOAN

31.03.2010

 

31.03.2009

 

Term Loan from State Bank of Hyderabad

44.441

60.629

Working Capital Loan from State Bank of Hyderabad

227.719

141.159

TOTAL

272.160

201.788

 

 

 

UNSECURED LOAN

 

 

From Corporate Bodies

90.000

90.000

From Shareholders

1.300

1.300

TOTAL

91.300

91.300

 

 

 

Banking Relations :

--

 

 

Auditors :

 

Name :

M. V. Narayana Reddy and Company

Chartered Accountants

Address :

504, Vijayasree Apartments, Behind Chermas Ameerpet, Hyderabad – 500 038, Andhra Pradesh, India

Tel. No.:

91-40-23744448 / 23743975

 

 

Associates/Subsidiaries :

·         Hetero Drugs Limited

·         Hetero Labs Limited

·         Symed Labs Limited

·         Chemipack India Private Limited 

 


 

CAPITAL STRUCTURE

 

AS ON 26.08.2010

 

Authorised Capital :

 

No. of Shares

Type

Value

Amount

 

 

 

 

100000

Equity Shares

Rs. 100 each

Rs. 10.000 millions

 

 

Issued Capital :

 

No. of Shares

Type

Value

Amount

 

 

 

 

92230

Equity Shares

Rs. 100 each

Rs.9.223 millions 

 

 

Issued, Subscribed & Paid-up Capital :

 

No. of Shares

Type

Value

Amount

 

 

 

 

70020

Equity Shares

Rs. 100 each

Rs.7.002 millions 

 

ADD: 22210 Equity Shares

Rs. 5 each

Rs. 0.111 million

 

 

 

Rs. 7.113 millions

 


 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2010

31.03.2009

31.03.2008

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

7.113

7.113

7.113

2] Share Application Money

0.000

0.000

0.000

3] Reserves & Surplus

272.340

248.439

193.957

4] (Accumulated Losses)

0.000

0.000

0.000

NETWORTH

279.453

255.552

201.070

LOAN FUNDS

 

 

 

1] Secured Loans

272.160

201.788

254.703

2] Unsecured Loans

91.300

91.300

95.223

TOTAL BORROWING

363.460

293.088

349.926

DEFERRED TAX LIABILITIES

41.535

38.569

33.825

 

 

 

 

TOTAL

684.448

587.209

584.821

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

296.365

291.741

275.466

Capital work-in-progress

0.000

0.000

0.000

 

 

 

 

INVESTMENT

0.100

0.100

0.100

DEFERREX TAX ASSETS

0.000

0.000

0.000

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

347.964

173.064

203.545

 

Sundry Debtors

102.347

186.215

125.061

 

Cash & Bank Balances

23.102

19.085

24.340

 

Other Current Assets

0.000

0.000

0.000

 

Loans & Advances

49.262

32.077

51.581

Total Current Assets

522.675

410.441

404.527

Less : CURRENT LIABILITIES & PROVISIONS

 

 

 

 

Sundry Creditors

117.988

68.828

81.084

 

Other Current Liabilities

15.751

33.694

14.134

 

Provisions

0.952

12.551

0.054

Total Current Liabilities

134.691

115.073

95.272

Net Current Assets

387.984

295.368

309.255

 

 

 

 

MISCELLANEOUS EXPENSES

0.000

0.000

0.000

 

 

 

 

TOTAL

684.448

587.209

584.821

 

 


PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2010

31.03.2009

31.03.2008

 

SALES

 

 

 

 

 

Sales

918.997

748.735

655.723

 

 

Other Income

5.503

6.884

1.881

 

 

TOTAL                                     (A)

924.500

755.619

657.604

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Cost of Materials

676.188

480.642

427.499

 

 

Manufacturing Expenses

78.905

63.288

68.888

 

 

Employees Remuneration

56.909

42.578

34.429

 

 

Administrative Expenses

15.338

22.640

14.130

 

 

TOTAL                                     (B)

827.340

609.148

544.946

 

 

 

 

 

Less

PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)      (C)

97.160

146.471

112.658

 

 

 

 

 

Less

FINANCIAL EXPENSES                         (D)

40.924

43.427

27.194

 

 

 

 

 

 

PROFIT BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                       (E)

56.236

103.044

85.464

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                     (F)

18.049

16.907

14.772

 

 

 

 

 

 

PROFIT BEFORE TAX (E-F)                               (G)

38.187

86.137

70.692

 

 

 

 

 

Less

TAX                                                                  (H)

14.286

31.655

26.914

 

 

 

 

 

 

PROFIT AFTER TAX (G-H)                                (I)

23.901

54.482

43.778

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

4.539

4.057

5.279

 

 

 

 

 

Less

APPROPRIATIONS

 

 

 

 

 

Transfer to General Reserve

25.200

54.000

45.000

 

BALANCE CARRIED TO THE B/S

3.240

4.539

4.057

 

 

 

 

 

 

Earnings Per Share (Rs.)

341.00

778

--

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2010

31.03.2009

31.03.2008

PAT / Total Income

(%)

2.58

7.21

6.65

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

4.15

11.50

10.74

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

4.66

12.26

10.39

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.13

0.33

0.35

 

 

 

 

 

Debt Equity Ratio

(Total Liability/Networth)

 

1.93

1.74

2.38

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

3.88

3.56

4.24

 

 

LOCAL AGENCY FURTHER INFORMATION

 

NOTE:

 

Registered office of the company has been shifted from 8-3-166/7/1, Hetero House, Erragadda, Hyderabad – 500 018, Andhra Pradesh, India to the present address w.e.f. 31.07.2009

 

 

REVIEW OF PERFORMANCE:

 

Despite challenging conditions, the company recorded satisfactory results. Sales and Other Income for the company stood at Rs. 924.501 millions as against Rs. 755.620 millions in the previous year.

 

The company has earned a net profit of Rs. 23.902 millions after providing for Taxes of Rs. 14.286 millions during the year under review, as against a net profit of Rs. 54.482 millions in the previous year after providing for Taxes of Rs. 31.656 millions. Due to lower realisation and high input costs, the profits have come down when compared to 2008-09

The company is well positioned to improve the performance in 2010-11

 

 

FIXED ASSETS:

 

·         Land

·         Factory Building

·         Plant and Machinery

·         Electrical Equipments

·         Lab Equipments

·         Furniture

·         Office Equipments

·         Computers

·         Vehicles

 

 


FORM 8

 

Corporate identity number of the company

U24239AP1990PLC012119

Name of the company

CIREX PHARMACEUTICALS LIMITED

Address of the registered office or of the principal place of  business in India of the company

7-2-A2, Hetero Corporate, Industrial Estate, Sanathnagar, Hyderabad 500018, Andhra Pradesh, India

This form is for

Modification of charge

Type of charge

·         Immovable property

·         Book debts

·         Movable property (not being pledge)

·         Floating charge

·         Others

Particular of charge holder

State Bank of Hyderabad

Industrial Estate, Sanathnagar Branch, Sanathnagr, Hyderabad – 500 018, Andhra Pradesh, India

Email: sanathnagar@sbhyd.co.in

Nature of instrument creating charge

Agreement of Hypothecations of Goods and Assets dated 17th February 2011

Memorandum of Deposit of Title Deeds dated 10th March, 2011

Date of instrument Creating the charge

17.02.2011

Amount secured by the charge

Rs. 450.000 millions

Brief of the principal terms an conditions and extent and operation of the charge

Rate of interest

As agreed between the Banker and Company

 

Terms of repayment

On Demand

 

Margin

For C.C - Raw Material, Stock in Process, Finished Goods 25%

For Packing Credit 25%

For L.C and B.G 5%

 

Extent and operation of the charge

First charge on all Present and Future current assets of the company

Extension of first charge on all Fixed Assets of the company, both present and future.

EM of company's factory land and bldg.

 

Short particulars of the property charged (Including location of the property)

First charge on all Present and Future Current Assets like Stocks, Raw Materials, Finished Goods, Stock in Process, and Receivables of the company

Extension of first charge on all Fixed Assets of the company, both preset and future.

EM of factory land and bldg. Gundlamachanoor Village, Hatnoor Mandal, Medak Dist.

Date of instrument modifying the charge

21.05.2009

Particulars of the present modification

Limits  in Millions

                                 Existing         Enhanced

 

CC (Hyp)                     180.000          220.000

Letter of Credit            145.000          190.000

Bank Guarantee           35.000            40.000

 

TOTAL                         360.000         450.000

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No records exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                              None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.44.94

UK Pound

1

Rs.71.89

Euro

1

Rs.64.09

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

6

PAID-UP CAPITAL

1~10

5

OPERATING SCALE

1~10

5

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

6

--PROFITABILIRY

1~10

6

--LIQUIDITY

1~10

5

--LEVERAGE

1~10

5

--RESERVES

1~10

7

--CREDIT LINES

1~10

5

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

YES

--AFFILIATION

YES/NO

NO

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

TOTAL

 

50

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

-

NB

                                       New Business

 

-

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.